M&A / Deals Parexel buys Vitrana to boost patient safety toolkit PharmaphorumContract research organisation Parexel has bought Vitrana and its AI-powered pharmacovigilance platform for an undisclosed sum.Read full story pharminent April 30, 2026 (Last updated: May 1, 2026) Pharmaphorum Contract research organisation Parexel has bought Vitrana and its AI-powered pharmacovigilance platform for an undisclosed sum. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: UniQure, in ‘symbolic’ win, to seek UK approval of Huntington’s gene therapyNext: Merck still sees ‘compelling’ outlook for Terns leukemia drug Related Stories M&A / Deals Gilead inks $140M API supply deal, tightening ties to Korean manufacturer pharminent May 22, 2026 M&A / Deals GBL joins CVC in 10.7bn takeover bid for Recordati pharminent May 22, 2026 M&A / Deals Gilead Sciences completes Tubulis acquisition for $5bn pharminent May 22, 2026
